Glasgow study reveals 'significant role' of genetics in Alzheimer's disease

A new study has revealed that genetics may play a more significant role in the development of Alzheimer's disease than previously thought.
The research, led by the University of Glasgow, published in the journal npj Dementia, found that while better memory, reasoning, and reaction times were linked to a lower risk of Alzheimer's disease up to 15 years later, this protective effect was significantly reduced in people with a higher genetic risk.
Researchers focused on the APOE e4 genotype, which is present in roughly one in four people and is the strongest known genetic predictor of late-onset Alzheimer's.
Read more: Glasgow drugs trial to use genetics to 'personalise' treatments
A single copy of the APOE e4 gene increases Alzheimer's risk threefold, while two copies raise the risk by twelvefold.
Dr Donald Lyall, senior lecturer in population brain health at the University of Glasgow's School of Health and Wellbeing, said: "Our study adds to the knowledge gap that exists on the relationship between genetic factors, cognitive health generally, and subsequent risk of dementia in later life.
"Our findings suggest that genetics plays a more significant role than previously thought and may influence the risk or protection conferred by other factors like premorbid cognitive health."
In the study, people with above-average reasoning ability were found to have a 36% lower risk of developing Alzheimer's within 15 years.
However, for those who also carried the APOE e4 gene, the risk reduction dropped to just 21%.
More strikingly, individuals with high reasoning skills but who carried the APOE e4 genotype were more likely to develop Alzheimer's than those with below-average reasoning but no genetic risk factor.
The researchers analysed data from over 252,000 UK Biobank participants aged 55 and older, with the average age at the start of the study being just over 62.
To ensure long-term accuracy, individuals diagnosed with Alzheimer's within two years of testing were excluded.
Researchers excluded individuals diagnosed with Alzheimer's within two years of cognitive testing.
The study reinforces the challenges in identifying effective therapies for Alzheimer's, particularly given the influence of genetic factors.
Read more: Public urged to shape health board's anti-racism strategy - how you can help
Dr Lyall said: "Our study has important implications regarding dementia; namely that genetics clearly plays a significant role in influencing someone's overall risk of Alzheimer's disease as they age."
The findings underscore the complex interplay between cognitive health and genetics and the challenges in developing therapies that can effectively prevent or treat Alzheimer's.
While cognitive resilience still matters, the research highlights the urgent need to understand genetic risk factors in the fight against one of the world's most devastating neurodegenerative conditions.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 hours ago

• Yahoo

David Hopkinson obituary

My friend and former colleague David Hopkinson, who has died aged 89, was director of the Medical Research Council's human biochemical genetics unit at University College London from 1976 until its closure in 2000. Hoppy, as he was universally known, had joined the unit at its inception in 1962 because in an earlier, more junior, position he had been one of the first medical scientists to describe molecular differences in human enzymes, long before DNA sequence differences were known about. The unit was established to research the extent and significance of genetic variation to human health. As its head, Hoppy expanded its focus to gene mapping and disease genetics while also moving into the new science of gene cloning and DNA sequencing. Born in Chesterfield, Derbyshire, to Albert Hopkinson, an iron and steelworks foreman, and Lilian (nee Siddal), a dressmaker, he went to Chesterfield grammar school, which fostered his early interest in organic chemistry. After completing a natural sciences degree at Cambridge University he qualified in medicine at the London hospital in 1959, working there until he joined the human biochemical genetics unit three years later. Hoppy was recruited by its inaugural head, Prof Harry Harris, becoming his right-hand man responsible for many of the unit's innovative experimental approaches, including developing novel methods of enzyme detection and electrophoresis. The unit moved in 1965 from its initial base at King's College to UCL, where I joined the unit three years later to study for a PhD under Harris. Hoppy remained there for the rest of his career. He published widely, and played an important part in teaching and supervision, being made full professor of London University in 1990. Twenty five years after his retirement, his role as mentor is remembered with great warmth by his former staff and students. Hoppy read widely and appreciated drama and music. A practical man who took pleasure in manual labour, he was an accomplished gardener and delighted in propagating plants and growing vegetables. He also enjoyed summers hiking in the Swiss Alps, and was a keen birdwatcher. In retirement, he studied architecture and German, and gained a first-class degree in geology at the Open University. He also spent many years as a volunteer at Chilterns' Citizens Advice in Chesham, Buckinghamshire. He is survived by his second wife, Prof Yvonne Edwards, and by three children, Paul, Susan and Ian, from his first marriage, to Josephine (nee Manze), which ended in divorce, and four grandchildren.

Yahoo

3 hours ago

• Yahoo

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Bloomberg

4 hours ago

• Bloomberg

UK Heat Wave Could Claim Nearly 600 Lives This Week, Experts Warn

Scientists have warned the elderly and other vulnerable groups in the UK are at risk of heat-related deaths this weekend, as a new study shows recent high temperatures could claim 570 lives in just over four days. Researchers at the London School of Hygiene & Tropical Medicine and Imperial College London published on Saturday a real-time analysis calculating the number of heat-related deaths expected from Thursday to Sunday.